Osteoclasts - The innate immune cells of the bone

Autoimmunity

Volumn 41, Issue 3, 2008, Pages 183-194

  Wu, Yalei ^a   Humphrey, Mary Beth ^a,c   Nakamura, Mary ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone; Differentiation; Innate immune receptors; Osteoclast; RANKL; Signal transduction

Indexed keywords

COLONY STIMULATING FACTOR 1; FC RECEPTOR; FC RECEPTOR GAMMA; IMMUNOGLOBULIN RECEPTOR; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ARTICLE; B LYMPHOCYTE; BONE DISEASE; BONE DYSPLASIA; BONE MARROW DEPRESSION; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONGENITAL MALFORMATION; ESTROGEN DEFICIENCY; FAMILIAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HEMATOPOIETIC CELL; HEREDITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; INNATE IMMUNITY; LEUKOENCEPHALOPATHY; NONHUMAN; OSSIFICATION; OSTEOCLAST; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PROTEIN DEFECT; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; BONE AND BONES; BONE RESORPTION; HUMANS; IMMUNITY, NATURAL; OSTEOCLASTS;

EID: 41449099766     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701693180     Document Type: Article

References (119)

1. Janeway Jr., CA and Medzhitov, R. (2002) Innate immune recognition. Annu Rev Immunol, 20, pp. 197-216.
2. Kollet, O., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., Samstein, RM, Goichberg, P. and Spiegel, A. (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med, 12:6, pp. 657-664.
3. Miller, SC (1978) Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone. J Cell Biol, 76:3, pp. 615-618.
4. Teitelbaum, SL (2007) Osteoclasts: What do they do and how do they do it?. Am J Pathol, 170:2, pp. 427-435.
5. Kollet, O., Dar, A. and Lapidot, T. (2007) The multiple roles of osteoclasts in host defense: Bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol, 25, pp. 51-69.
6. Taylor, PR, Martinez-Pomares, L., Stacey, M., Lin, H-H, Brown, GD and Gordon, S. (2005) Macrophage receptors and immune recognition. Annu Rev Immunol, pp. 901-944.
7. Roodman, GD, Kurihara, N., Ohsaki, Y., Kukita, A., Hosking, D., Demulder, A., Smith, JF and Singer, FR (1992) Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest, 89:1, pp. 46-52.
8. Grassi, F., Piacentini, A., Cristino, S., Toneguzzi, S., Cavallo, C., Facchini, A. and Lisignoli, G. (2003) Human osteoclasts express different CXC chemokines depending on cell culture substrate: Molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol, 120:5, pp. 391-400.
9. Goldring, SR (2003) Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int, 73:2, pp. 97-100.
10. Boyle, WJ, Simonet, WS and Lacey, DL (2003) Osteoclast differentiation and activation. Nature, 423:6937, pp. 337-342.
11. Teitelbaum, SL and Ross, FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet, 4:8, pp. 638-649.
12. Villa, A., Vezzoni, P. and Frattini, A. (2006) Osteopetroses and immunodeficiencies in humans. Curr Opin Allergy Clin Immunol, 6:6, pp. 421-427.
13. Walker, DG (1975) Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science, 190:4216, pp. 784-785.
14. Coccia, PF, Krivit, W., Cervenka, J., Clawson, C., Kersey, JH, Kim, TH, Nesbit, ME, Ramsay, NK, Warkentin, PI and Teitelbaum, SL (1980) Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med, 302:13, pp. 701-708.
15. Lacey, DL, Timms, E., Tan, HL, Kelley, MJ, Dunstan, CR, Burgess, T., Elliott, R., Colombero, A., Elliott, G. and Scully, S. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93:2, pp. 165-176.
16. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M. and Murakami, A. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95:7, pp. 3597-3602.
17. Wong, BR, Josien, R. and Choi, Y. (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol, 65:6, pp. 715-724.
18. Lum, L., Wong, BR, Josien, R., Becherer, JD, Erdjument-Bromage, H., Schlondorff, J., Tempst, P., Choi, Y. and Blobel, CP (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem, 274:19, pp. 13613-13618.
19. Theill, LE, Boyle, WJ and Penninger, JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol, 20, pp. 795-823.
20. Dougall, WC, Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, ME and Maliszewski, CR (1999) RANK is essential for osteoclast and lymph node development. Genes Dev, 13:18, pp. 2412-2424.
21. Simonet, WS, Lacey, DL, Dunstan, CR, Kelley, M., Chang, MS, Luthy, R., Nguyen, HQ, Wooden, S., Bennett, L. and Boone, T. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89:2, pp. 309-319.
22. Hofbauer, LC and Schoppet, M. (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Assoc, 292:4, pp. 490-495.
23. Li, J., Sarosi, I., Yan, XQ, Morony, S., Capparelli, C., Tan, HL, McCabe, S., Elliott, R., Scully, S. and Van, G. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA, 97:4, pp. 1566-1571.
24. Kong, YY, Yoshida, H., Sarosi, I., Tan, HL, Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, AJ, Van, G. and Itie, A. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397:6717, pp. 315-323.
25. Bucay, N., Sarosi, I., Dunstan, CR, Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, HL, Xu, W. and Lacey, DL (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12:9, pp. 1260-1268.
26. Hsu, H., Lacey, DL, Dunstan, CR, Solovyev, I., Colombero, A., Timms, E., Tan, HL, Elliott, G., Kelley, MJ and Sarosi, I. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA, 96:7, pp. 3540-3545.
27. Hughes, AE, Ralston, SH, Marken, J., Bell, C., MacPherson, H., Wallace, RG, van Hul, W., Whyte, MP, Nakatsuka, K. and Hovy, L. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet, 24:1, pp. 45-48.
28. Whyte, MP and Mumm, S. (2004) Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact, 4:3, pp. 254-267.
29. Whyte, MP, Obrecht, SE, Finnegan, PM, Jones, JL, Podgornik, MN, McAlister, WH and Mumm, S. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med, 347:3, pp. 175-184.
30. Cundy, T., Hegde, M., Naot, D., Chong, B., King, A., Wallace, R., Mulley, J., Love, DR, Seidel, J. and Fawkner, M. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet, 11:18, pp. 2119-2127.
31. Arko, B., Prezelj, J., Komel, R., Kocijancic, A., Hudler, P. and Marc, J. (2002) Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab, 87:9, pp. 4080-4084.
32. Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S. and Inoue, J. (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. Embo J, 20:6, pp. 1271-1280.
33. Lomaga, MA, Yeh, WC, Sarosi, I., Duncan, GS, Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G. and Kaufman, S. (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev, 13:8, pp. 1015-1024.
34. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T. and Inoue, J. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 3:6, pp. 889-901.
35. Anderson, D., Maraskovsky, E., Billingsley, WL, Dougall, WC, Tometsko, ME, Roux, ER, Teepe, MC, DuBose, RF, Cosman, D. and Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 390, pp. 175-179.
36. Felix, R., Hofstetter, W., Wetterwald, A., Cecchini, MG and Fleisch, H. (1994) Role of colony-stimulating factor-1 in bone metabolism. J Cell Biochem, 55:3, pp. 340-349.
37. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T. and Shultz, LD (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 345:6274, pp. 442-444.
38. Zou, W., Kitaura, H., Reeve, J., Long, F., Tybulewicz, VL, Shattil, SJ, Ginsberg, MH, Ross, FP and Teitelbaum, SL (2007) Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol, 176:6, pp. 877-888.
39. Faccio, R., Takeshita, S., Zallone, A., Ross, FP and Teitelbaum, SL (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest, 111:5, pp. 749-758.
40. Kitaura, H., Zhou, P., Kim, HJ, Novack, DV, Ross, FP and Teitelbaum, SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest, 115:12, pp. 3418-3427.
41. Watts, TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol, 23, pp. 23-68.
42. Humphrey, MB, Lanier, LL and Nakamura, MC (2005) Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev, 208, pp. 50-65.
43. Samelson, LE (2002) Signal transduction mediated by the T cell antigen receptor: The role of adapter proteins. Annu Rev Immunol, 20, pp. 371-394.
44. Pitcher, LA and van Oers, NS (2003) T-cell receptor signal transmission: Who gives an ITAM?. Trends Immunol, 24:10, pp. 554-560.
45. Reth, M. (1989) Antigen receptor tail clue. Nature, 338:6214, pp. 383-384.
46. Abram, CL and Lowell, CA (2007) The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE, 2007:377, p. re2.
47. Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T. and Kodama, T. (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 428:6984, pp. 758-763.
48. Mocsai, A., Humphrey, MB, Van Ziffle, JA, Hu, Y., Burghardt, A., Spusta, SC, Majumdar, S., Lanier, LL, Lowell, CA and Nakamura, MC (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA, 101:16, pp. 6158-6163.
49. Faccio, R., Zou, W., Colaianni, G., Teitelbaum, SL and Ross, FP (2003) High dose M-CSF partially rescues the Dap12-/-osteoclast phenotype. J Cell Biochem, 90:5, pp. 871-883.
50. Lanier, LL and Bakker, AB (2000) The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today, 21:12, pp. 611-614.
51. Takai, T., Li, M., Sylvestre, D., Clynes, R. and Ravetch, JV (1994) FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell, 76:3, pp. 519-529.
52. Humphrey, MB, Ogasawara, K., Yao, W., Spusta, SC, Daws, MR, Lane, NE, Lanier, LL and Nakamura, MC (2003) The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res
53. Humphrey, MB, Daws, MR, Spusta, SC, Niemi, EC, Torchia, JA, Lanier, LL, Seaman, WE and Nakamura, MC (2006) TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res, 21:2, pp. 237-245.
54. Hentunen, TA, Jackson, SH, Chung, H., Reddy, SV, Lorenzo, J., Choi, SJ and Roodman, GD (1999) Characterization of immortalized osteoclast precursors developed from mice transgenic for both bcl-X(L) and simian virus 40 large T antigen. Endocrinology, 140:7, pp. 2954-2961.
55. Athanasou, NA and Quinn, J. (1990) Immunophenotypic differences between osteoclasts and macrophage polykaryons: Immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol, 43:12, pp. 997-1003.
56. Maeda, A., Kurosaki, M. and Kurosaki, T. (1998) Paired immunoglobulin-like receptor (PIR)-A is involved in activating mast cells through its association with Fc receptor gamma chain. J Exp Med, 188:5, pp. 991-995.
57. Taylor, LS and McVicar, DW (1999) Functional association of FcepsilonRIgamma with arginine(632) of paired immunoglobulin-like receptor (PIR)-A3 in murine macrophages. Blood, 94:5, pp. 1790-1796.
58. Merck, E., Gaillard, C., Gorman, DM, Montero-Julian, F., Durand, I., Zurawski, SM, Menetrier-Caux, C., Carra, G., Lebecque, S. and Trinchieri, G. (2004) OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells. Blood, 104:5, pp. 1386-1395.
59. Ishikawa, S., Arase, N., Suenaga, T., Saita, Y., Noda, M., Kuriyama, T., Arase, H. and Saito, T. (2004) Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). Int Immunol, 16:7, pp. 1019-1025.
60. Kim, N., Takami, M., Rho, J., Josien, R. and Choi, Y. (2002) A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med, 195:2, pp. 201-209.
61. Merck, E., de Saint-Vis, B., Scuiller, M., Gaillard, C., Caux, C., Trinchieri, G. and Bates, EE (2005) Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. Blood, 105:9, pp. 3623-3632.
62. Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen, V., Hakola, P., Bakker, AB, Phillips, JH and Pekkarinen, P. (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet, 25:3, pp. 357-361.
63. Paloneva, J., Mandelin, J., Kiialainen, A., Bohling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, YT and Peltonen, L. (2003) DAP12/ TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med, 198:4, pp. 669-675.
64. Paloneva, J., Autti, T., Raininko, R., Partanen, J., Salonen, O., Puranen, M., Hakola, P. and Haltia, M. (2001) CNS manifestations of Nasu-Hakola disease: A frontal dementia with bone cysts. Neurology, 56:11, pp. 1552-1558.
65. Verloes, A., Maquet, P., Sadzot, B., Vivario, M., Thiry, A. and Franck, G. (1997) Nasu-Hakola syndrome: Polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J Med Genet, 34:9, pp. 753-757.
66. Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R. and Salmaggi, A. (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet, 71:3, pp. 656-662.
67. Cella, M., Buonsanti, C., Strader, C., Kondo, T., Salmaggi, A. and Colonna, M. (2003) Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med, 198:4, pp. 645-651.
68. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A. and Nakamura, A. (2003) Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest, 111:3, pp. 323-332.
69. Chaabane, M., Larnaout, A., Sebai, R., Nagi, S., Touibi, S. and Hentati, F. (2000) Nasu-Hakola disease in two Tunisian siblings: New radiological findings. Neuroradiology, 42:5, pp. 375-378.
70. Daws, MR, Sullam, PM, Niemi, EC, Chen, TT, Tchao, NK and Seaman, WE (2003) Pattern recognition by TREM-2: Binding of anionic ligands. J Immunol, 171:2, pp. 594-599.
71. Takegahara, N., Takamatsu, H., Toyofuku, T., Tsujimura, T., Okuno, T., Yukawa, K., Mizui, M., Yamamoto, M., Prasad, DV and Suzuki, K. (2006) Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol, 8:6, pp. 615-622.
72. Hamerman, JA, Tchao, NK, Lowell, CA and Lanier, LL (2005) Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol, 6:6, pp. 579-586.
73. Hamerman, JA, Jarjoura, JR, Humphrey, MB, Nakamura, MC, Seaman, WE and Lanier, LL (2006) Cutting edge: Inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol, 177:4, pp. 2051-2055.
74. Turnbull, IR, Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M. and Colonna, M. (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol, 177:6, pp. 3520-3524.
75. Klesney-Tait, J., Turnbull, IR and Colonna, M. (2006) The TREM receptor family and signal integration. Nat Immunol, 7:12, pp. 1266-1273.
76. Hamerman, JA and Lanier, LL (2006) Inhibition of immune responses by ITAM-bearing receptors. Sci STKE, 2006:320, p. re1.
77. Turnbull, IR and Colonna, M. (2007) Activating and inhibitory functions of DAP12. Nat Rev Immunol, 7:2, pp. 155-161.
78. Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T. and Miyamoto, K. (2005) DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med, 202:3, pp. 345-351.
79. Zhou, Z., Immel, D., Xi, CX, Bierhaus, A., Feng, X., Mei, L., Nawroth, P., Stern, DM and Xiong, WC (2006) Regulation of osteoclast function and bone mass by RAGE. J Exp Med, 203:4, pp. 1067-1080.
80. Ding, KH, Wang, ZZ, Hamrick, MW, Deng, ZB, Zhou, L., Kang, B., Yan, SL, She, JX, Stern, DM and Isales, CM (2006) Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun, 340:4, pp. 1091-1097.
81. Lin, YL, de Villiers, WJ, Garvy, B., Post, SR, Nagy, TR, Safadi, FF, Faugere, MC, Wang, G., Malluche, HH and Williams, JP (2007) The effect of class a scavenger receptor deficiency in bone. J Biol Chem, 282:7, pp. 4653-4660.
82. Sato, N., Takahashi, N., Suda, K., Nakamura, M., Yamaki, M., Ninomiya, T., Kobayashi, Y., Takada, H., Shibata, K. and Yamamoto, M. (2004) MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med, 200:5, pp. 601-611.
83. Veillette, A., Latour, S. and Davidson, D. (2002) Negative regulation of immunoreceptor signaling. Annu Rev Immunol, 20, pp. 669-707.
84. Aoki, K., Didomenico, E., Sims, NA, Mukhopadhyay, K., Neff, L., Houghton, A., Amling, M., Levy, JB, Horne, WC and Baron, R. (1999) The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: Increased resorption and osteopenia in me(v)/me(v) mutant mice. Bone, 25:3, pp. 261-267.
85. Takeshita, S., Namba, N., Zhao, JJ, Jiang, Y., Genant, HK, Silva, MJ, Brodt, MD, Helgason, CD, Kalesnikoff, J. and Rauh, MJ (2002) SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med, 8:9, pp. 943-949.
86. Umeda, S., Beamer, WG, Takagi, K., Naito, M., Hayashi, S., Yonemitsu, H., Yi, T. and Shultz, LD (1999) Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am J Pathol, 155:1, pp. 223-233.
87. Chung, DH, Humphrey, MB, Nakamura, MC, Ginzinger, DG, Seaman, WE and Daws, MR (2003) CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol, 171:12, pp. 6541-6548.
88. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K. and Shima, N. (2000) Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med, 191, pp. 275-286.
89. Nakashima, T., Kobayashi, Y., Yamasaki, S., Kawakami, A., Eguchi, K., Sasaki, H. and Sakai, H. (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun, 275:3, pp. 768-775.
90. Brandstrom, H., Bjorkman, T. and Ljunggren, O. (2001) Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun, 280:3, pp. 831-835.
91. Hofbauer, LC, Dunstan, CR, Spelsberg, TC, Riggs, BL and Khosla, S. (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun, 250:3, pp. 776-781.
92. Hofbauer, LC, Lacey, DL, Dunstan, CR, Spelsberg, TC, Riggs, BL and Khosla, S. (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 25:3, pp. 255-259.
93. Moreno, JL, Kaczmarek, M., Keegan, AD and Tondravi, M. (2003) IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. Blood, 102:3, pp. 1078-1086.
94. Kermanac'h, N Saidenberg, Bessis, N., Cohen-Solal, M., De Vernejoul, MC and Boissier, MC (2002) Osteoprotegerin and inflammation. Eur Cytokine Netw, 13:2, pp. 144-153.
95. Palmqvist, P., Lundberg, P., Persson, E., Johansson, A., Lundgren, I., Lie, A., Conaway, HH and Lerner, UH (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 281:5, pp. 2414-2429.
96. Palmqvist, P., Persson, E., Conaway, HH and Lerner, UH (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol, 169:6, pp. 3353-3362.
97. Horwood, NJ, Elliott, J., Martin, TJ and Gillespie, MT (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology, 139:11, pp. 4743-4746.
98. Ahlen, J., Andersson, S., Mukohyama, H., Roth, C., Backman, A., Conaway, HH and Lerner, UH (2002) Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone, 31:1, pp. 242-251.
99. Nagata, N., Kitaura, H., Yoshida, N. and Nakayama, K. (2003) Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: Involvement of IFN-gamma possibly induced from non-T cell population. Bone, 33:4, pp. 721-732.
100. Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S. and Iwakura, Y. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203:12, pp. 2673-2682.
101. Dai, SM, Nishioka, K. and Yudoh, K. (2004) Interleukin (IL)18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: Comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis, 63:11, pp. 1379-1386.
102. Takayanagi, H., Kim, S. and Taniguchi, T. (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res, 4, pp. S227-S232.
103. Yan, T., Riggs, BL, Boyle, WJ and Khosla, S. (2001) Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem, 83:2, pp. 320-325.
104. Kobayashi, Y., Hashimoto, F., Miyamoto, H., Kanaoka, K., Miyazaki-Kawashita, Y., Nakashima, T., Shibata, M., Kobayashi, K., Kato, Y. and Sakai, H. (2000) Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J Bone Miner Res, 15:10, pp. 1924-1934.
105. Ishida, A., Fujita, N., Kitazawa, R. and Tsuruo, T. (2002) Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone. J Biol Chem, 277:29, pp. 26217-26224.
106. Thirunavukkarasu, K., Miles, RR, Halladay, DL, Yang, X., Galvin, RJ, Chandrasekhar, S., Martin, TJ and Onyia, JE (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem, 276:39, pp. 36241-36250.
107. Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, WJ, Lacey, DL and Riggs, BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest, 111:8, pp. 1221-1230.
108. Hofbauer, LC, Khosla, S., Dunstan, CR, Lacey, DL, Spelsberg, TC and Riggs, BL (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140:9, pp. 4367-4370.
109. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, SI, Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K. and Kuriyama, M. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139:3, pp. 1329-1337.
110. Vidal, NO, Brandstrom, H., Jonsson, KB and Ohlsson, C. (1998) Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol, 159:1, pp. 191-195.
111. Lee, SK and Lorenzo, JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology, 140:8, pp. 3552-3561.
112. Huang, JC, Sakata, T., Pfleger, LL, Bencsik, M., Halloran, BP, Bikle, DD and Nissenson, RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res, 19:2, pp. 235-244.
113. Thomas, RJ, Guise, TA, Yin, JJ, Elliott, J., Horwood, NJ, Martin, TJ and Gillespie, MT (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140:10, pp. 4451-4458.
114. Yun, TJ, Chaudhary, PM, Shu, GL, Frazer, JK, Ewings, MK, Schwartz, SM, Pascual, V., Hood, LE and Clark, EA (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol, 161:11, pp. 6113-6121.
115. Liu, XH, Kirschenbaum, A., Yao, S. and Levine, AC (2005) Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology, 146:4, pp. 1991-1998.
116. Suda, K., Udagawa, N., Sato, N., Takami, M., Itoh, K., Woo, JT, Takahashi, N. and Nagai, K. (2004) Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J Immunol, 172:4, pp. 2504-2510.
117. Rubin, J., Ackert-Bicknell, CL, Zhu, L., Fan, X., Murphy, TC, Nanes, MS, Marcus, R., Holloway, L., Beamer, WG and Rosen, CJ (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab, 87:9, pp. 4273-4279.
118. Asagiri, M., Sato, K., Usami, T., Ochi, S., Nishina, H., Yoshida, H., Morita, I., Wagner, EF, Mak, TW and Serfling, E. (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med, 202:9, pp. 1261-1269.
119. Shinohara, M. and Takayanagi, H. (2007) Novel osteoclast signaling mechanisms. Curr Osteoporos Rep, 5:2, pp. 67-72.